SEC 13F Intelligence

Managers / Q3 2024 · view latest →

Aldebaran Capital, LLC

CIK 0001448430 · 10293 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46290 · 317-818-7827

Reported Value
$110M
Q3 2024
Positions
37
Filings on Record
14
2019–present window
Filed
Nov 13, 2024
original filing

Summary

Aldebaran Capital, LLC reported $110M in U.S.-listed holdings across 37 positions for Q3 2024.

Its largest position, BRK/B, represents 18.5% of the portfolio.

Compared with Q2 2024, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+4.3%
vs prior filed quarter
Top-10 Concentration
+74.9%
share of reported value
Largest Position
+18.5%
Berkshire Hathaway

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $97MQ4 ’22Q1 ’23: $98MQ2 ’23: $97MQ2 ’23Q3 ’23: $98MQ4 ’23: $98MQ4 ’23Q1 ’24: $105MQ2 ’24: $107MQ2 ’24Q3 ’24: $110MQ4 ’24: $105MQ4 ’24Q1 ’25: $106MQ2 ’25: $101MQ2 ’25Q3 ’25: $109MQ4 ’25: $112MQ4 ’25Q1 ’26: $131Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.3%Other: 10.3%ETP: 8.2%Equity WRT: 0.2%
  • Common Stock · 81.3% · $89M
  • Other · 10.3% · $11M
  • ETP · 8.2% · $9M
  • Equity WRT · 0.2% · $247,835

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ANTXAN2 THEREAPEUTICS INCNEW+100.5K100.5K+$107,535$107,535
PMVPPMV PHARMACEUTICALS INCADDED+87.0K438.3K+$83,981$652,995
FFORD MTR CO DELADDED+5.0K25.6K+$11,913$270,864
CO2ACATO CORP NEWADDED+199.2K1.12M+$485,819$6M
ACRSACLARIS THERAPEUTICS INCADDED+185.0K1.04M+$255,658$1M
ISHARES TR RUS MDCP VALADDED+2.5K41.3K+$776,270$5M
9HIHILLENBRAND INCHELD−59540.2K−$514,946$1M
RENEO PHARMACEUTICALS INCHELD+4.5K452.1K+$92,697$768,597

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

34 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BRK/BBERKSHIRE HATHAWAY INC DELCL B NEW · CL A19.76%$22M44.0K
2MSFTMICROSOFT CORPhistory →COM9.39%$10M23.9K
3BUNGE LIMITEDCOM8.95%$10M101.4K
4OXYOCCIDENTAL PETE CORPCOM · star W EXP 08/03/2028.44%$9M182.9K
5LLYLILLY ELI & COhistory →COM6.29%$7M7.8K
6BACBANK AMERICA CORPhistory →COM5.25%$6M144.9K
7CO2ACATO CORP NEWhistory →CL A5.12%$6M1.12M
8ISHARES TR RUS MDCP VALETF4.98%$5M41.3K
9SUSUNCOR ENERGY INC NEWhistory →COM4.30%$5M127.7K
10CHVCHEVRON CORP NEWhistory →COM3.91%$4M29.1K
11ABRDN ETFSBBRG ALL COMD K1 · BBG INDUSTRL MET3.23%$4M170.6K
12JPMJPMORGAN CHASE & COhistory →COM2.29%$3M11.9K
13BACVERIZON COMMUNICATIONS INChistory →COM1.77%$2M43.2K
14RELLRICHARDSON ELECTRS LTDhistory →COM1.72%$2M152.7K
15ENBENBRIDGE INChistory →COM1.62%$2M43.8K
16FCXFREEPORT-MCMORAN INChistory →CL B1.47%$2M32.3K
17PATKPATRICK INDS INChistory →COM1.26%$1M9.7K
18TECXTECTONIC THERAPEUTIC INChistory →COM1.16%$1M42.0K
19ACRSACLARIS THERAPEUTICS INChistory →COM1.10%$1M1.04M
209HIHILLENBRAND INChistory →COM1.02%$1M40.2K
21IESCIES HLDGS INCCOM0.99%$1M5.4K
22CENXCENTURY ALUM COCOM0.94%$1M63.4K
23AMLXAMYLYX PHARMACEUTICALS INCCOM0.80%$874,162269.8K
24RENEO PHARMACEUTICALS INCCOM0.70%$768,597452.1K
25TECK/BTECK RESOURCES LTDCL B0.63%$695,47113.3K
26PMVPPMV PHARMACEUTICALS INCCOM0.60%$652,995438.3K
27ABXBARRICK GOLD CORPCOM0.54%$596,28230.0K
28MBINMERCHANTS BANCORP INDCOM0.42%$455,22010.1K
29DUKE ENERGY CORP NEWCOM NEW0.38%$415,0803.6K
30FFORD MTR CO DELCOM0.25%$270,86425.6K
31GENERAL ELECTRIC COCOM0.23%$251,0001.3K
32EXMOCEXXON MOBIL CORPCOM0.20%$223,6561.9K
33PGPROCTER AND GAMBLE COCOM0.20%$218,3091.3K
34ANTXAN2 THEREAPEUTICS INCCOM0.10%$107,535100.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$131M43May 7, 202613F-HRchanges · EDGAR ↗
Q4 2025$112M35Feb 12, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M33Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M34Aug 12, 202513F-HRchanges · EDGAR ↗
Q1 2025$106M41May 13, 202513F-HRchanges · EDGAR ↗
Q4 2024$105M37Feb 12, 202513F-HRchanges · EDGAR ↗
Q3 2024$110M37Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$107M36Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$105M33May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$98M31Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$98M33Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$97M33Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$98M34May 11, 202313F-HRchanges · EDGAR ↗
Q4 2022$97M34Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.